Clinical Trial Results, Licensing Agreements, Breakthrough Research and Development Programs - Research Report on Pfizer, Merck,

   Clinical Trial Results, Licensing Agreements, Breakthrough Research and
  Development Programs - Research Report on Pfizer, Merck, Rockwell Medical,
                        GlaxoSmithKline, and Novartis

PR Newswire

NEW YORK, September 18, 2013

NEW YORK, September 18, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Rockwell Medical Technologies
Inc. (NASDAQ: RMTI), GlaxoSmithKline plc (NYSE: GSK), and Novartis AG (NYSE:
NVS). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On September 3, 2013, Pfizer Inc. (Pfizer) and Bristol-Myers Squibb Company
(Bristol-Myers) announced results of a post-hoc subanalysis of Phase III
ARISTOTLE trial, demonstrating the efficacy and safety of Eliquis compared to
warfarin for the prevention of stroke or systemic embolism in nonvalvular
atrial fibrillation (NVAF) patients. According to the Company, the results
from the subanalysis were consistent with the overall ARISTOTLE trial and
demonstrated that Eliquis compared with warfarin reduced stroke or systemic
embolism, caused fewer major bleeding events, and reduced all-cause mortality
in NVAF patients with or without VHD. "This subanalysis provides better
insight into the efficacy and safety of apixaban in nonvalvular atrial
fibrillation patients with certain types of valvular heart disease, which are
common in an elderly population," said Study Lead Author Dr. Alvaro Avezum of
the Dante Pazzanese Institute of Cardiology in San Paulo, Brazil. The Full
Research Report on Pfizer Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/d702_PFE]

--

Merck & Co. Inc. Research Report 

On September 11, 2013, Merck & Co. Inc (Merck) and AstraZeneca, announced a
worldwide licensing agreement for Merck's oral small molecule inhibitor of
WEE1 kinase (MK-1775), which is currently being evaluated in Phase IIa
clinical studies in combination with standard-of-care therapies for the
treatment of patients with certain types of ovarian cancer. Pursuant to the
terms of the agreement, Merck will receive a $50 million upfront fee from
AstraZeneca, along with contingent future payments related to the development
and regulatory milestones, plus sales related payments and tiered royalties.
Further, as per the agreement, AstraZeneca will be responsible for all future
clinical development, manufacturing and marketing. The Full Research Report on
Merck & Co. Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/430d_MRK]

--

Rockwell Medical Technologies Inc. Research Report

On September 4, 2013, Rockwell Medical Technologies Inc. (Rockwell Medical)
announced successful top-line results from its long-term CRUISE-2 Phase 3
efficacy study of SFP, the Company's late-stage investigational iron-delivery
drug for the treatment of iron deficiency in chronic kidney disease patients
receiving hemodialysis. According to the Company, the study met the primary
and secondary endpoints, demonstrating a statistically significant mean change
in hemoglobin from baseline to End-of-Treatment. The Company further stated
that the study is the second and final study of two identical Phase 3 efficacy
studies to provide clinical data required for the Company to file a New Drug
Application (NDA) with the US FDA. Rob Chioini, Founder, Chairman and CEO of
Rockwell Medical stated, "As we were with CRUISE-1, we are thrilled with the
successful outcome of this CRUISE-2 efficacy study. This second Phase 3 study
produced identical results to the first in demonstrating statistical
significance and meeting the primary efficacy endpoint." The Full Research
Report on Rockwell Medical Technologies Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/3079_RMTI]

--

GlaxoSmithKline plc Research Report

On September 12, 2013, GlaxoSmithKline plc's (GlaxoSmithKline) joint venture
company with Pfizer, ViiV Healthcare, announced initial results from its Phase
IIIb/IV FLAMINGO (ING114915) study. According to the Company, the study
compared once-daily regimens containing 50mg dolutegravir with once-daily
regimens containing a protease inhibitor (PI) in treatment-naïve adults with
HIV-1. The Company stated that in the period of 48 weeks 90% of patients
treated with the dolutegravir regimen were virologically suppressed compared
to those treated with the darunavir regimen. Dr John Pottage, Chief Medical
Officer at ViiV Healthcare said, "This is the first study in our clinical
programme to compare dolutegravir to a boosted protease inhibitor in
treatment-naïve patients. PIs are often selected as part of a first-line
regimen for treatment-naïve patients, so these data provide important
information regarding dolutegravir as a treatment choice for these patients."
The Full Research Report on GlaxoSmithKline plc - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/2a35_GSK]

--

Novartis AG Research Report

On September 13, 2013, Novartis AG (Novartis) issued a press release stating
that a remarkable progress has been achieved in Malaria programs in
sub-Saharan Africa. According to a recent research unveiled at the Tanzania
Malaria Control Forum in Dar es Salaam, the rate of malaria among Tanzanian
children between ages of six months to five years have reduced to half from
2008 to 2012. Novartis said that these successes have been credited to
fighting malaria on several fronts, including scaling up bed nets, diagnostic
testing, treatment and surveillance. According to the Company, the Novartis
Foundation for Sustainable Development has been working with key stakeholders
in Tanzania since 2003, to improve access to quality healthcare while the
Novartis Institute for Tropical Diseases (NITD) in Singapore conducts research
to develop next generation malaria therapies. Novartis said that taking
preventive measures and having access to effective medications, African
countries can continue to make progress toward malaria elimination. The Full
Research Report on Novartis AG - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/9b6d_NVS]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com



SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)